ProQR Therapeutics N.V. PRQR
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 135.17% | -49.98% | 18.87% | -20.25% | -36.17% |
| Total Other Revenue | -- | -- | -77.52% | -74.56% | 6.79% |
| Total Revenue | 125.82% | -52.33% | 15.92% | -22.13% | -35.13% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 125.82% | -52.33% | 15.92% | -22.13% | -35.13% |
| SG&A Expenses | 4.57% | 32.43% | 8.59% | 1.03% | 68.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.05% | 12.07% | 3.86% | 18.92% | 70.04% |
| Operating Income | 26.19% | -40.30% | 1.45% | -37.68% | -258.77% |
| Income Before Tax | 26.66% | -47.63% | -4.68% | -44.35% | -343.39% |
| Income Tax Expenses | 42.65% | -- | -- | -- | 109.48% |
| Earnings from Continuing Operations | 26.56% | -47.63% | -4.69% | -44.35% | -377.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.56% | -47.63% | -4.69% | -44.35% | -377.04% |
| EBIT | 26.19% | -40.30% | 1.45% | -37.68% | -258.77% |
| EBITDA | 28.15% | -42.07% | 1.72% | -40.59% | -322.44% |
| EPS Basic | 29.65% | -47.57% | 1.20% | -11.92% | -269.58% |
| Normalized Basic EPS | 29.79% | -47.46% | 1.28% | -11.88% | -244.12% |
| EPS Diluted | 31.72% | -44.58% | 1.20% | -11.10% | -283.66% |
| Normalized Diluted EPS | 29.79% | -47.46% | 1.28% | -11.88% | -244.12% |
| Average Basic Shares Outstanding | 4.38% | 0.06% | 5.96% | 28.97% | 28.99% |
| Average Diluted Shares Outstanding | 4.38% | 0.06% | 5.96% | 28.97% | 28.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |